The actions to be funded under this topic are expected to achieve the following:
a. contribute to one or more of IHI JU’s expected impacts linked to Specific Objective 1 as set out in the IHI JU SRIA, i.e.:
b. contribute to strengthening the competitiveness of the EU’s health industry, via increased economic activity in the development of health technologies, in particular, integrated health solutions, thus fostering European technological leadership and the digital transformation of our societies.
The actions are expected to contribute to EU programmes, initiatives and policies such as the European Green Deal, Europe’s Beating Cancer Plan, the EU Mission on Cancer, the European Virtual Human Twins Initiative, the European Health Emergency Preparedness and Response Authority (HERA), the European Commission’s proposal for the European Health Data Space (EHDS), and the EU Artificial Intelligence Act1, where relevant.
1 EU Artificial Intelligence Act | Up-to-date developments and analyses of the EU AI Act
Expected Outcome:
Applicants must define the outcomes expected to be achieved by the project, ensuring that they contribute to at least one of IHI JU’s potential outputs linked to the IHI JU’s Specific Objective 1 ‘contribute towards a better understanding of the determinants of health and priority disease areas’, as set out in the IHI JU Strategic Research and Innovation Agenda (SRIA).
Actions (projects) to be funded under this topic must deliver results that address public health needs and support the development of future health innovations that are safe, people-centred, effective, cost-effective and affordable for patients and for health care systems.
The expected outcomes may cover the entire spectrum of care and may be health technologies centred around disease areas and/or key themes such as prevention, precision diagnostics, personalised medicine, and chronic disease management. They may also include solutions for key enablers such as digital data and solutions, artificial intelligence (AI), regulatory science, greener and more sustainable healthcare, and implementation science1.
1 In the context of IHI, ‘implementation science’ refers to the development and piloting of methods and strategies that facilitate the uptake of evidence-based practice and research outcomes into regular use (e.g. translation of results, uptake, scale-up, piloting in healthcare).
Scope:
With a view to harnessing new science and technologies, this topic aims to fund pre-competitive research and innovation for novel tools, methods, technologies etc. that will foster the development of health innovations to prevent, intercept, diagnose, treat, and manage diseases and enable recovery more efficiently.
Accordingly, applicants must assemble a collaborative public-private partnership consortium reflecting the integrative and cross-sectoral nature of IHI JU, that is capable of addressing the challenge(s) and scope of the IHI JU Specific Objective 1 ‘contribute towards a better understanding of the determinants of health and priority disease areas’, as defined in IHI JU’s legal basis1 and described in more detail in the IHI JU SRIA2:
Opening date
16 January 2025
Deadline date
29 April 2025 17:00:00 Brussels time
Applicants should consider the following points in their proposals:
a. address an unmet public health need based on at least one of the below:
b. demonstrate the ability to translate research into innovative solutions that can be integrated/implemented into the healthcare ecosystem (taking into consideration the fragmented nature of European healthcare systems) and/or in industrial processes.
When applicable, proposals should consider relevant aspects of patient-centricity, with the help of the most suitable health technologies and/or social innovations, including open science, and taking demographic trends into account as relevant.
If applicable, applicants are expected to consider the potential regulatory impact of the anticipated project’s outputs, and, as relevant, develop a regulatory strategy and interaction plan for generating appropriate evidence and for engaging with regulators and other bodies in a timely manner, e.g. EU national competent authorities, notified bodies for medical devices and in-vitro diagnostic devices, health technology assessment (HTA) agencies, and the European Medicines Agency (EMA) through existing opportunities for regulatory support services, such as the Innovation Task Force and qualification advice.
As relevant, consideration should also be given to the Health Data Access Bodies that will be established under the forthcoming European Health Data Space Regulation3 in the context of secondary use of data.
Applicants should consider relevant existing initiatives/projects to ensure synergies and complementarities and avoid unnecessary overlap and duplication of efforts. The proposal should include a plan on how to synergise with these initiatives.
Sponsor Institute/Organizations: Innovative Health Initiative (IHI)
Sponsor Type:
Address: Avenue de la Toison d'Or 56-60 1060 Brussels Belgium
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Apr 29, 2025
Apr 29, 2025
$8,678,813
Affiliation: Innovative Health Initiative (IHI)
Address: Avenue de la Toison d'Or 56-60 1060 Brussels Belgium
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.